Cartesian Therapeutics, Inc. — Director's Dealing 2022

Jun 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-06-01

Reporting Person: Brunn Carsten (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-01	Common Stock	M	10938	—	Acquired	534390	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-01	Restricted Stock Units	$	M	10938	Disposed		Common Stock (10938.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date.